BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

Assembly Biosciences Inc. (NASDAQ:ASMB) said Richard Colonno will retire as CSO, virology, on June 1. He is succeeded by William Delaney, who spent 20 years at Gilead Sciences Inc. (NASDAQ:GILD), most recently serving as executive...
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio...
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

Praxis’ neurology pipeline emerged from genetic data that found neuronal imbalances to be at the root of several disorders that were previously thought to be unrelated. The company debuted this month with $100 million in...
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

Flagship’s Repertoire aims to identify which TCRs and antigens matter in disease and apply those insights to biomarkers and therapies, starting with a cytokine-loaded T cell candidate for cancer. Repertoire Immune Medicines Inc. emerged in...
BioCentury | May 16, 2020
Management Tracks

Bingham to lead U.K. push for a COVID-19 vaccine

The U.K. has picked longtime biotech investor Kate Bingham to chair the government’s Vaccine Taskforce, the latest example of the country deploying its industry expertise to combat COVID-19. Bingham will report directly to Prime Minister...
BioCentury | May 8, 2020
Product Development

Moderna’s Bancel highlights speed, flexibility of mRNA platform as COVID-19 vaccine heads to Phase II

As Moderna readies a Phase II trial of its COVID-19 vaccine just 12 weeks after the virus was sequenced, CEO Stéphane Bancel told BioCentury that the speed of the company mRNA platform could also be...
BioCentury | Apr 29, 2020
Product Development

Efficacy data for risdiplam could position Roche’s oral SMA therapy ahead of Spinraza

Even with a PDUFA delay for Roche’s SMA therapy earlier this month, efficacy data from the Phase II/III FIREFISH trial of risdiplam released Tuesday cast a favorable light on the oral therapy when compared with...
BioCentury | Apr 23, 2020
Finance

Market recalibrates Biogen’s valuation as aducanumab filing is delayed

Biogen’s aducanumab roller-coaster ride continued Wednesday as investors reassessed the risk for the Alzheimer’s therapy following a roughly six-month delay for the company’s BLA submission. Biogen Inc. (NASDAQ:BIIB) disclosed Wednesday plans to push back an...
BioCentury | Apr 16, 2020
Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

TScan, Novartis partner to develop TCR therapies  TScan Therapeutics Inc. entered an agreement with Novartis AG (NYSE:NVS; SIX:NOVN) to discover and develop TCR-engineered T cell therapies. Novartis will pay a technology access fee and research...
Items per page:
1 - 10 of 4866
BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

Assembly Biosciences Inc. (NASDAQ:ASMB) said Richard Colonno will retire as CSO, virology, on June 1. He is succeeded by William Delaney, who spent 20 years at Gilead Sciences Inc. (NASDAQ:GILD), most recently serving as executive...
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio...
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

Praxis’ neurology pipeline emerged from genetic data that found neuronal imbalances to be at the root of several disorders that were previously thought to be unrelated. The company debuted this month with $100 million in...
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

Flagship’s Repertoire aims to identify which TCRs and antigens matter in disease and apply those insights to biomarkers and therapies, starting with a cytokine-loaded T cell candidate for cancer. Repertoire Immune Medicines Inc. emerged in...
BioCentury | May 16, 2020
Management Tracks

Bingham to lead U.K. push for a COVID-19 vaccine

The U.K. has picked longtime biotech investor Kate Bingham to chair the government’s Vaccine Taskforce, the latest example of the country deploying its industry expertise to combat COVID-19. Bingham will report directly to Prime Minister...
BioCentury | May 8, 2020
Product Development

Moderna’s Bancel highlights speed, flexibility of mRNA platform as COVID-19 vaccine heads to Phase II

As Moderna readies a Phase II trial of its COVID-19 vaccine just 12 weeks after the virus was sequenced, CEO Stéphane Bancel told BioCentury that the speed of the company mRNA platform could also be...
BioCentury | Apr 29, 2020
Product Development

Efficacy data for risdiplam could position Roche’s oral SMA therapy ahead of Spinraza

Even with a PDUFA delay for Roche’s SMA therapy earlier this month, efficacy data from the Phase II/III FIREFISH trial of risdiplam released Tuesday cast a favorable light on the oral therapy when compared with...
BioCentury | Apr 23, 2020
Finance

Market recalibrates Biogen’s valuation as aducanumab filing is delayed

Biogen’s aducanumab roller-coaster ride continued Wednesday as investors reassessed the risk for the Alzheimer’s therapy following a roughly six-month delay for the company’s BLA submission. Biogen Inc. (NASDAQ:BIIB) disclosed Wednesday plans to push back an...
BioCentury | Apr 16, 2020
Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

TScan, Novartis partner to develop TCR therapies  TScan Therapeutics Inc. entered an agreement with Novartis AG (NYSE:NVS; SIX:NOVN) to discover and develop TCR-engineered T cell therapies. Novartis will pay a technology access fee and research...
Items per page:
1 - 10 of 4866